Is Trifluoperazina [INN-Spanish] Safe in Breastfeeding

I am a breastfeeding mother and i want to know if it is safe to use Trifluoperazina [INN-Spanish]? Is Trifluoperazina [INN-Spanish] safe for nursing mother and child? Does Trifluoperazina [INN-Spanish] extracts into breast milk? Does Trifluoperazina [INN-Spanish] has any long term or short term side effects on infants? Can Trifluoperazina [INN-Spanish] influence milk supply or can Trifluoperazina [INN-Spanish] decrease milk supply in lactating mothers?

Tranquillizer drug similar to prochlorperazine that may produce galactorrhea by increasing prolactin release.

Limited information indicates that maternal doses of Trifluoperazina [INN-Spanish] up to 10 mg daily do not affect the breastfed infant. Very limited long-term follow-up data indicate no adverse developmental effects when other phenothiazines are used alone. Because there is little published experience with Trifluoperazina [INN-Spanish] during breastfeeding, other antipsychotic agents may be preferred, especially wile nursing an newborn or preterm infant.

One infant was breastfed from birth during maternal Trifluoperazina [INN-Spanish] 10 mg daily in addition to clonazepam 0.25 mg daily and valproic acid 500 mg daily. No adverse effects in the infant were reported by the mother (follow-up time unspecified).[2] One mother began taking Trifluoperazina [INN-Spanish] (dosage unspecified) 2 months postpartum while breastfeeding her infant. She also started olanzapine 10 mg daily, paroxetine and procyclidine (dosages unspecified). The infant experiences no adverse reactions.[3] Two mothers taking Trifluoperazina [INN-Spanish] 5 and 10 mg per day orally breastfed their infants from 1 week and 8 weeks of age, respectively. Mental and psychomotor development were measured at various time up to 30 months of age and were found to be normal.[1]

Phenothiazines cause galactorrhea in 26 to 40% of female patients.[4][5] Hyperprolactinemia appears to be the cause of the galactorrhea.[6][7][8] The hyperprolactinemia is caused by the drug's dopamine-blocking action in the tuberoinfundibular pathway.[9]